Galectin Therapeutics reported $11.29M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Gilead Sciences USD 3.95B 19.57B Jun/2026
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 973.64M 4.65B Jun/2026
Merck USD 15.77B 2.4B Jun/2026